FibroBiologics, Inc. - Common Stock (NQ:FBLG)

0.8755 -0.0308 (-3.40%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2026 Add to My Watchlist

Price and Volume

Volume	58,508
Open	0.9070
Bid (Size)	0.8805 (100)
Ask (Size)	0.8874 (100)
Prev. Close	0.9063
Today's Range	0.8755 - 0.9300
52wk Range	0.7310 - 14.68
Shares Outstanding	38,262,586
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing

June 22, 2026

Allowed claims directly support the Company’s ongoing Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers

June 16, 2026

Company continues to advance CYWC628 manufacturing with second GMP drug product run released for shipment to Australia and a third run nearing completion

From FibroBiologics, Inc.

Via GlobeNewswire

Performance

YTD	-81.8%	-81.8%
1 Month	-21.8%	-21.8%
3 Month	-34.2%	-34.2%
6 Month	-80.5%	-80.5%
1 Year	-92.7%	-92.7%

More News

FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers

June 03, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial ↗

June 03, 2026

Via Benzinga

FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting

May 22, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

May 18, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus

May 11, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics CEO Issues Letter to Shareholders

May 05, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring

May 04, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial

May 04, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update

April 30, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026

April 30, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Compliant with All Nasdaq Listing Requirements

April 20, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity

April 10, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

FibroBiologics Announces Closing of $3 Million Public Offering

April 02, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Which stocks are moving before the opening bell on Wednesday? ↗

April 01, 2026

Via Chartmill

FibroBiologics Announces Pricing of $3 Million Public Offering

March 31, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Top movers in Tuesday's after hours session ↗

March 31, 2026

Via Chartmill

FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial

March 31, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

March 31, 2026

Via Chartmill

Which stocks are experiencing notable movement on Tuesday? ↗

March 31, 2026

Via Chartmill

The market is filled with gapping stocks in Tuesday's session. ↗

March 31, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

March 25, 2026

Via Chartmill

FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Bid Price Requirement

March 25, 2026

From FibroBiologics, Inc.

Via GlobeNewswire

The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed

March 18, 2026

From USA News Group

Via GlobeNewswire

Frequently Asked Questions

Is FibroBiologics, Inc. - Common Stock publicly traded?

Yes, FibroBiologics, Inc. - Common Stock is publicly traded.

What exchange does FibroBiologics, Inc. - Common Stock trade on?

FibroBiologics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for FibroBiologics, Inc. - Common Stock?

The ticker symbol for FibroBiologics, Inc. - Common Stock is FBLG on the Nasdaq Stock Market

What is the current price of FibroBiologics, Inc. - Common Stock?

The current price of FibroBiologics, Inc. - Common Stock is 0.8755

When was FibroBiologics, Inc. - Common Stock last traded?

The last trade of FibroBiologics, Inc. - Common Stock was at 07/02/26 04:00 PM ET

What is the market capitalization of FibroBiologics, Inc. - Common Stock?

The market capitalization of FibroBiologics, Inc. - Common Stock is 33.50M

How many shares of FibroBiologics, Inc. - Common Stock are outstanding?

FibroBiologics, Inc. - Common Stock has 33M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.